chr7:55181378:C>T Detail (hg38) (EGFR, EGFR-AS1)

Information

Genome

Assembly Position
hg19 chr7:55,249,071-55,249,071 View the variant detail on this assembly version.
hg38 chr7:55,181,378-55,181,378

HGVS

Type Transcript Protein
RefSeq NM_005228.3:c.2369C>T NP_005219.2:p.Thr790Met
NM_001346897.1:c.2234C>T NP_001333826.1:p.Thr745Met
Ensemble ENST00000275493.7:c.2369C>T ENST00000275493.7:p.Thr790Met
Summary

MGeND

Clinical significance Pathogenic drug response
Variant entry 7
GWAS entry
Disease area statistics Show details

Frequency

JP HGVD:[No Data.]
ToMMo:[No Data.]
NCBN:[No Data.]
NCBN(Hondo):[No Data.]
NCBN(Ryukyu):[No Data.]
East asia ExAC:<0.001

Prediction

ClinVar

Clinical Significance drug response
Review star
Show details
Links
Type Database ID Link
Gene MIM 131550 OMIM
HGNC 3236 HGNC
Ensembl ENSG00000146648 Ensembl
NCBI NCBI
Gene Cards Gene Cards
OncoKB OncoKB
Type Database ID Link
Variant TogoVar
COSMIC COSM6240 COSMIC
MONDO
Disease area statistics
MGeND
Clinical significance Last evaluated Condition Origin Submission ID Submitter Institute Citation Comment Image
drug response 2017/12/14 lung adenocarcinoma somatic MGS000017
(TMGS000052) 		Kohei Miyazono Tokyo University
drug response 2017/12/19 lung adenocarcinoma somatic MGS000017
(TMGS000052) 		Kohei Miyazono Tokyo University
drug response 2018/04/26 lung adenocarcinoma (metastasis) somatic MGS000017
(TMGS000052) 		Kohei Miyazono Tokyo University
Pathogenic other unknown MGS000001
(TMGS000137) 		Kenjiro Kosaki Keio University
Pathogenic other unknown MGS000001
(TMGS000154) 		Kenjiro Kosaki Keio University
Pathogenic other somatic MGS000001
(TMGS000179) 		Kenjiro Kosaki Keio University
ClinVar
Clinical significance Last evaluated Review status Condition Origin Links
protective 2009-12-24 no assertion criteria provided Nonsmall cell lung cancer, resistance to tyrosine kinase inhibitor in unknown Detail
drug response 2020-10-30 no assertion criteria provided somatic Detail
Pathogenic Likely pathogenic 2016-03-10 no assertion criteria provided Non-small cell lung carcinoma germline somatic Detail
drug response 2021-03-24 reviewed by expert panel germline Detail
Likely pathogenic 2016-05-13 no assertion criteria provided lung carcinoma somatic Detail
Likely pathogenic 2024-01-31 criteria provided, single submitter EGFR-related lung cancer germline Detail
Likely pathogenic 2023-07-18 criteria provided, single submitter Hereditary cancer-predisposing syndrome germline Detail
Likely pathogenic 2020-09-08 criteria provided, single submitter not provided germline Detail
drug response 2021-03-24 reviewed by expert panel germline Detail
Pathogenic criteria provided, single submitter lung cancer germline Detail
Pathogenic 2023-09-29 criteria provided, single submitter Inflammatory skin and bowel disease, neonatal, 2 unknown Detail
Likely pathogenic no assertion criteria provided lung adenocarcinoma somatic Detail
CIViC
Disease Drug EL ET ED CS VO TR Pubmed Links
lung adenocarcinoma Gefitinib,Erlotinib B Predictive Supports Resistance Somatic 3 23470965 Detail
lung adenocarcinoma Osimertinib C Predictive Supports Sensitivity/Response Somatic 1 26181354 Detail
lung non-small cell carcinoma Osimertinib A Predictive Supports Sensitivity/Response Somatic 5 26729184 Detail
lung non-small cell carcinoma Erlotinib,Afatinib,Gefitinib B Predictive Supports Resistance Somatic 3 27304188 Detail
lung non-small cell carcinoma Afatinib B Predictive Supports Resistance Somatic 4 24035188 Detail
lung non-small cell carcinoma Osimertinib A Predictive Supports Sensitivity/Response Somatic 5 27959700 Detail
lung adenocarcinoma Osimertinib C Predictive Supports Sensitivity/Response Somatic 2 26269204 Detail
lung non-small cell carcinoma Gefitinib C Predictive Supports Resistance Somatic 15737014 Detail
lung non-small cell carcinoma Gefitinib C Predictive Supports Resistance Somatic 17020982 Detail
lung non-small cell carcinoma Lapatinib D Predictive Supports Resistance Somatic 4 18408761 Detail
lung non-small cell carcinoma Dacomitinib D Predictive Supports Sensitivity/Response Somatic 3 18089823 Detail
lung non-small cell carcinoma Neratinib D Predictive Supports Sensitivity/Response Somatic 2 16818618 Detail
lung non-small cell carcinoma Afatinib D Predictive Supports Sensitivity/Response Somatic 2 18408761 Detail
lung non-small cell carcinoma Afatinib D Predictive Supports Sensitivity/Response Somatic 2 21732342 Detail
lung non-small cell carcinoma Canertinib D Predictive Supports Sensitivity/Response Somatic 2 18408761 Detail
lung non-small cell carcinoma Erlotinib A Predictive Supports Resistance Somatic 5 25668228 Detail
lung non-small cell carcinoma Gefitinib B Predictive Supports Resistance Somatic 3 15728811 Detail
lung non-small cell carcinoma Dacomitinib B Predictive Supports Resistance Somatic 4 21430269 Detail
lung non-small cell carcinoma Pemetrexed,Erlotinib C Predictive Supports Sensitivity/Response Somatic 3 24636847 Detail
lung non-small cell carcinoma Staurosporine E Predictive Supports Sensitivity/Response Somatic 1 24658966 Detail
lung non-small cell carcinoma B Prognostic Supports Poor Outcome Somatic 4 24623981 Detail
lung non-small cell carcinoma B Prognostic Supports Poor Outcome Somatic 4 24729716 Detail
cancer Erlotinib D Predictive Supports Somatic 3 19147750 Detail
lung cancer Multikinase Inhibitor AEE788,Gefitinib D Predictive Supports Resistance Somatic 5 18227510 Detail
lung non-small cell carcinoma Rociletinib B Predictive Supports Sensitivity/Response Somatic 4 25923550 Detail
lung non-small cell carcinoma Rociletinib D Predictive Supports Sensitivity/Response Somatic 3 24065731 Detail
lung non-small cell carcinoma Osimertinib D Predictive Supports Sensitivity/Response Somatic 3 24893891 Detail
lung non-small cell carcinoma Osimertinib B Predictive Supports Sensitivity/Response Somatic 4 25923549 Detail
lung non-small cell carcinoma Osimertinib B Predictive Supports Sensitivity/Response Somatic 3 26720284 Detail
lung non-small cell carcinoma Osimertinib,Rociletinib D Predictive Supports Sensitivity/Response Somatic 2 26515464 Detail
DisGeNET
Score Disease name Description Source Pubmed Links
0.008 Xenograft Model Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors ef... BeFree 19850869 Detail
0.003 Xenograft Model Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors ef... BeFree 19850869 Detail
0.002 Xenograft Model Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors ef... BeFree 19850869 Detail
0.160 Malignant neoplasm of lung Gefitinib greatly enhanced NK cell cytotoxicity to lung cancer cells with EGFR L... BeFree 23937717 Detail
0.206 Lung Neoplasms Pharmacologic inhibition of β-catenin suppressed EGFR-L858R-T790M mutated lung t... BeFree 25164010 Detail
0.002 Xenograft Model Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors ef... BeFree 19850869 Detail
0.129 squamous cell carcinoma Some of these EGFR-mutated PDXs do not respond to erlotinib: LU1868 containing L... BeFree 22948846 Detail
0.385 Non-small cell lung carcinoma The in vivo antitumor efficacy study demonstrated that compound 3x significantly... BeFree 24053674 Detail
0.277 squamous cell carcinoma We used four NSCLC cell lines-A549 (wild-type EGFR), H1650 (mutant EGFR; del E74... BeFree 24583857 Detail
0.002 Xenograft Model Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors ef... BeFree 19850869 Detail
0.277 squamous cell carcinoma Some of these EGFR-mutated PDXs do not respond to erlotinib: LU1868 containing L... BeFree 22948846 Detail
0.002 Xenograft Model Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors ef... BeFree 19850869 Detail
0.080 Carcinoma of lung Gefitinib greatly enhanced NK cell cytotoxicity to lung cancer cells with EGFR L... BeFree 23937717 Detail
0.385 Non-small cell lung carcinoma We used four NSCLC cell lines-A549 (wild-type EGFR), H1650 (mutant EGFR; del E74... BeFree 24583857 Detail
0.080 Carcinoma of lung Lower gefitinib dose led to earlier resistance acquisition before emergence of T... BeFree 24033722 Detail
0.385 Non-small cell lung carcinoma Eligible patients included those with relapsed or recurrent advanced NSCLC who p... BeFree 22011666 Detail
0.004 breast carcinoma We examined the mRNA expression of C terminus-binding protein-interacting protei... BeFree 23407556 Detail
0.160 Malignant neoplasm of lung Highly sensitive detection of EGFR T790M mutation using colony hybridization pre... BeFree 22899358 Detail
0.160 Malignant neoplasm of lung Hepatocyte growth factor reduces susceptibility to an irreversible epidermal gro... BeFree 20008840 Detail
0.160 Malignant neoplasm of lung We investigated the effect of CK2 inhibition in lung cancer cells with T790M-med... BeFree 25486409 Detail
0.360 adenocarcinoma Acquired resistance of pulmonary adenocarcinoma to initially successful targeted... BeFree 17649787 Detail
0.137 Small cell carcinoma of lung EGFR T790M secondary mutation, MET gene amplification, and transformation to sma... BeFree 24939008 Detail
0.385 Non-small cell lung carcinoma Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by d... BeFree 25405807 Detail
0.385 Non-small cell lung carcinoma Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies ... BeFree 24919575 Detail
0.160 Malignant neoplasm of lung EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histolo... BeFree 24029120 Detail
0.385 Non-small cell lung carcinoma These inhibitors also show effective inhibition of signaling by T790M-mutant EGF... BeFree 15897464 Detail
<0.001 Malignant neoplasm of breast We examined the mRNA expression of C terminus-binding protein-interacting protei... BeFree 23407556 Detail
0.385 Non-small cell lung carcinoma Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib:... BeFree 24675505 Detail
0.011 Carcinoma of lung Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyr... BeFree 23592446 Detail
0.360 adenocarcinoma In conclusion, the minor EGFR T790M mutations were present in 13% of EGFR-TKI-na... BeFree 24842519 Detail
<0.001 Non-small cell lung carcinoma We examined the mRNA expression of C terminus-binding protein-interacting protei... BeFree 23407556 Detail
0.160 Malignant neoplasm of lung Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyr... BeFree 23592446 Detail
0.080 breast carcinoma We examined the mRNA expression of C terminus-binding protein-interacting protei... BeFree 23407556 Detail
0.080 Carcinoma of lung Clinical outcome according to the level of preexisting epidermal growth factor r... BeFree 24737599 Detail
<0.001 Non-small cell lung carcinoma The molecular beacon-based approach enabled rapid and sensitive detection of the... BeFree 20805561 Detail
0.104 Malignant neoplasm of breast We examined the mRNA expression of C terminus-binding protein-interacting protei... BeFree 23407556 Detail
0.080 Carcinoma of lung Hepatocyte growth factor reduces susceptibility to an irreversible epidermal gro... BeFree 20008840 Detail
0.160 Malignant neoplasm of lung EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase acti... BeFree 17510392 Detail
0.080 Carcinoma of lung Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung ... BeFree 25450875 Detail
0.011 Malignant neoplasm of lung It will be clinically valuable to investigate the involvement of HGF-MET-mediate... BeFree 20008840 Detail
0.002 thymoma The PC-9-derived NSCLC cell lines PC-9ER and PC-9ZD, resistant to EGFR-TKI due t... BeFree 24698130 Detail
0.011 Malignant neoplasm of lung Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lun... BeFree 19351834 Detail
0.008 Progressive cGVHD EGFR T790M was identified from plasma DNA in 54% (15 of 28) of patients with pri... BeFree 19351754 Detail
0.080 Carcinoma of lung Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyr... BeFree 23592446 Detail
0.360 adenocarcinoma Novel D761Y and common secondary T790M mutations in epidermal growth factor rece... BeFree 17085664 Detail
0.385 Non-small cell lung carcinoma These results suggest that EGFR T790M mutation and c-MET amplification can occur... BeFree 19381876 Detail
0.141 Non-small cell lung carcinoma Most non-small cell lung cancer (NSCLC) tumors with activating mutations of the ... BeFree 20530710 Detail
0.385 Non-small cell lung carcinoma Together, our results suggest that the identified T cell epitopes might provide ... BeFree 24223798 Detail
<0.001 Carcinoma of lung Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein o... BeFree 23045273 Detail
<0.001 Refractory cancer Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lun... BeFree 19351834 Detail
0.385 Non-small cell lung carcinoma Emergence of epidermal growth factor receptor T790M mutation during chronic expo... BeFree 17699786 Detail
0.385 Non-small cell lung carcinoma It shows preclinical efficacy in NSCLC with common EGFR-activating mutations and... BeFree 24086949 Detail
0.385 Non-small cell lung carcinoma In clinical practice, most patients with non small cell lung cancer (NSCLC) who ... BeFree 22160570 Detail
0.080 Carcinoma of lung Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant hum... BeFree 24842595 Detail
0.023 Malignant neoplasm of lung Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyr... BeFree 23592446 Detail
0.004 Carcinoma, Small Cell At present, secondary resistance mechanisms associated with progression are bett... BeFree 23911281 Detail
0.008 Carcinoma of lung Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein o... BeFree 23045273 Detail
0.360 adenocarcinoma In human lung adenocarcinomas harboring EGFR mutations, a second-site point muta... BeFree 18093943 Detail
0.023 Malignant neoplasm of lung It will be clinically valuable to investigate the involvement of HGF-MET-mediate... BeFree 20008840 Detail
0.160 Malignant neoplasm of lung Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung ... BeFree 25450875 Detail
<0.001 Carcinoma, Small Cell At present, secondary resistance mechanisms associated with progression are bett... BeFree 23911281 Detail
0.009 Malignant neoplasm of lung Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein o... BeFree 23045273 Detail
0.385 Non-small cell lung carcinoma Post-progression tumor specimens were prospectively collected for T790M mutation... BeFree 24035188 Detail
<0.001 Non-small cell lung carcinoma We examined the mRNA expression of C terminus-binding protein-interacting protei... BeFree 23407556 Detail
0.160 Malignant neoplasm of lung To define the incidence of EGFR T790M, we reviewed 2774 sequentially tested pati... BeFree 24478319 Detail
0.004 Carcinoma, Large Cell We analyzed 147 NSCLC tissues [70 adenocarcinomas (AD), 62 squamous cell carcino... BeFree 21635547 Detail
0.009 Malignant neoplasm of lung Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein o... BeFree 23045273 Detail
0.018 Non-small cell lung carcinoma Most non-small cell lung cancer (NSCLC) tumors with activating mutations of the ... BeFree 20530710 Detail
0.080 Carcinoma of lung Lung cancer cell lines made resistant to EGFR-TKIs by the gatekeeper EGFR-T790M ... BeFree 24386407 Detail
<0.001 Malignant neoplasm of lung Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein o... BeFree 23045273 Detail
<0.001 Malignant neoplasm of lung Cell line-based assays showed that Aki1 constitutively associates with mutant EG... BeFree 23045273 Detail
0.011 Malignant neoplasm of lung High-level HGF expression was detected more frequently than EGFR T790M secondary... BeFree 22052230 Detail
0.200 Adenocarcinoma of lung (disorder) Usefulness of nanofluidic digital PCR arrays to quantify T790M mutation in EGFR-... BeFree 25560642 Detail
0.080 Carcinoma of lung AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutat... BeFree 25923549 Detail
0.002 Refractory cancer Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lun... BeFree 19351834 Detail
0.007 Small cell carcinoma of lung These efforts have revealed several acquired resistance mechanisms and candidate... BeFree 22736441 Detail
0.009 Malignant neoplasm of lung Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein o... BeFree 23045273 Detail
0.009 Carcinoma of lung Reciprocal and complementary role of MET amplification and EGFR T790M mutation i... BeFree 21062933 Detail
0.008 Progressive Neoplastic Disease EGFR T790M was identified from plasma DNA in 54% (15 of 28) of patients with pri... BeFree 19351754 Detail
0.008 Xenograft Model Furthermore, both agents and their combination almost completely prevented TKI-r... BeFree 23515752 Detail
<0.001 Carcinoma, Small Cell At present, secondary resistance mechanisms associated with progression are bett... BeFree 23911281 Detail
<0.001 Refractory cancer Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lun... BeFree 19351834 Detail
0.009 Carcinoma of lung Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyr... BeFree 23592446 Detail
0.360 Malignant neoplasm of breast We examined the mRNA expression of C terminus-binding protein-interacting protei... BeFree 23407556 Detail
0.080 Carcinoma of lung EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histolo... BeFree 24029120 Detail
0.080 Carcinoma of lung Highly sensitive detection of EGFR T790M mutation using colony hybridization pre... BeFree 22899358 Detail
0.160 Malignant neoplasm of lung The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autopha... BeFree 25382705 Detail
0.385 Non-small cell lung carcinoma Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-smal... BeFree 19351754 Detail
0.160 Malignant neoplasm of lung Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant hum... BeFree 24842595 Detail
0.006 Carcinoma of lung Hepatocyte growth factor reduces susceptibility to an irreversible epidermal gro... BeFree 20008840 Detail
0.009 adenosquamous carcinoma We analyzed 147 NSCLC tissues [70 adenocarcinomas (AD), 62 squamous cell carcino... BeFree 21635547 Detail
0.385 Non-small cell lung carcinoma Enhanced anticancer effect of the combination of BIBW2992 and thymidylate syntha... BeFree 20530710 Detail
0.385 Non-small cell lung carcinoma : Our results imply that blockade of the TGF-β signaling pathway combined with c... BeFree 23334091 Detail
0.006 Carcinoma of lung The three major clinically relevant mechanisms of acquired resistance to epiderm... BeFree 22592212 Detail
0.141 Non-small cell lung carcinoma Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)... BeFree 25117641 Detail
0.298 Lung Neoplasms MET amplification occurs with or without T790M mutations in EGFR mutant lung tum... BeFree 18093943 Detail
<0.001 Malignant neoplasm of lung HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibi... BeFree 17671147 Detail
0.023 Malignant neoplasm of lung High-level HGF expression was detected more frequently than EGFR T790M secondary... BeFree 22052230 Detail
0.008 Carcinoma of lung Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein o... BeFree 23045273 Detail
0.002 thymoma The PC-9-derived NSCLC cell lines PC-9ER and PC-9ZD, resistant to EGFR-TKI due t... BeFree 24698130 Detail
0.385 Non-small cell lung carcinoma Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCL... BeFree 21796416 Detail
0.385 Non-small cell lung carcinoma Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts sho... BeFree 22215752 Detail
0.080 Carcinoma of lung Biochemical analyses of transfected cells and growth inhibition studies with lun... BeFree 15737014 Detail
0.385 Non-small cell lung carcinoma DNA from 124 pretreatment tissue samples from patients with advanced non-small-c... BeFree 25450875 Detail
0.009 Carcinoma of lung It will be clinically valuable to investigate the involvement of HGF-MET-mediate... BeFree 20008840 Detail
<0.001 Carcinoma, Small Cell At present, secondary resistance mechanisms associated with progression are bett... BeFree 23911281 Detail
0.080 breast carcinoma We examined the mRNA expression of C terminus-binding protein-interacting protei... BeFree 23407556 Detail
<0.001 Carcinoma of lung Cell line-based assays showed that Aki1 constitutively associates with mutant EG... BeFree 23045273 Detail
0.277 squamous cell carcinoma We analyzed 147 NSCLC tissues [70 adenocarcinomas (AD), 62 squamous cell carcino... BeFree 21635547 Detail
0.009 Non-small cell lung cancer metastatic There is limited information available concerning the prevalence of primary T790... BeFree 24789720 Detail
0.080 Carcinoma of lung EGFR T790M mutation: a double role in lung cancer cell survival? BeFree 19096299 Detail
0.080 Carcinoma of lung The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autopha... BeFree 25382705 Detail
0.004 Malignant neoplasm of breast We examined the mRNA expression of C terminus-binding protein-interacting protei... BeFree 23407556 Detail
0.021 Malignant neoplasm of lung Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein o... BeFree 23045273 Detail
0.160 Malignant neoplasm of lung Quantification of epidermal growth factor receptor T790M mutant transcripts in l... BeFree 19961825 Detail
0.385 Non-small cell lung carcinoma Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung canc... BeFree 23266614 Detail
0.013 Metastatic malignant neoplasm to brain There is a possibility to detect the primary T790M mutation in brain metastases ... BeFree 24789720 Detail
<0.001 Malignant neoplasm of lung Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein o... BeFree 23045273 Detail
0.080 Carcinoma of lung We investigated the effect of CK2 inhibition in lung cancer cells with T790M-med... BeFree 25486409 Detail
0.011 Malignant neoplasm of lung Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lun... BeFree 19351834 Detail
0.024 Malignant neoplasm of lung Although the EGF receptor tyrosine kinase inhibitors (EGFR-TKI) erlotinib and ge... BeFree 22844075 Detail
0.385 Non-small cell lung carcinoma A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired re... BeFree 21953013 Detail
<0.001 Small cell carcinoma of lung These efforts have revealed several acquired resistance mechanisms and candidate... BeFree 22736441 Detail
0.080 Carcinoma of lung Detection of low-level EGFR T790M mutation in lung cancer tissues. BeFree 21635547 Detail
0.023 Malignant neoplasm of lung Reciprocal and complementary role of MET amplification and EGFR T790M mutation i... BeFree 21062933 Detail
0.002 thymoma The PC-9-derived NSCLC cell lines PC-9ER and PC-9ZD, resistant to EGFR-TKI due t... BeFree 24698130 Detail
0.385 Non-small cell lung carcinoma Although epidermal growth factor receptor (EGFR) kinase inhibitors are effective... BeFree 19459856 Detail
0.011 Small cell carcinoma of lung EGFR T790M secondary mutation, MET gene amplification, and transformation to sma... BeFree 24939008 Detail
0.160 Malignant neoplasm of lung The T790M mutation in EGFR accounts for approximately half of all lung cancer ca... BeFree 26058074 Detail
0.160 Malignant neoplasm of lung AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutat... BeFree 25923549 Detail
0.080 Carcinoma of lung To define the incidence of EGFR T790M, we reviewed 2774 sequentially tested pati... BeFree 24478319 Detail
0.011 Malignant neoplasm of lung It will be clinically valuable to investigate the involvement of HGF-MET-mediate... BeFree 20008840 Detail
0.160 Malignant neoplasm of lung Inherited susceptibility to lung cancer may be associated with the T790M drug re... BeFree 16258541 Detail
0.080 Carcinoma of lung Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibi... BeFree 23588221 Detail
0.385 Non-small cell lung carcinoma Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-pat... BeFree 24768581 Detail
0.137 Small cell carcinoma of lung These efforts have revealed several acquired resistance mechanisms and candidate... BeFree 22736441 Detail
0.011 Malignant neoplasm of lung Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyr... BeFree 23592446 Detail
<0.001 Carcinoma, Small Cell At present, secondary resistance mechanisms associated with progression are bett... BeFree 23911281 Detail
0.122 Small cell carcinoma of lung These efforts have revealed several acquired resistance mechanisms and candidate... BeFree 22736441 Detail
0.298 Lung Neoplasms Rapamycin prevents the development and progression of mutant epidermal growth fa... BeFree 24931608 Detail
0.360 adenocarcinoma A lung biopsy from the left lower lobe disclosed an adenocarcinoma which harbore... BeFree 17618013 Detail
0.080 Carcinoma of lung Inherited susceptibility to lung cancer may be associated with the T790M drug re... BeFree 16258541 Detail
0.141 Non-small cell lung carcinoma These results suggest that EGFR T790M mutation and c-MET amplification can occur... BeFree 19381876 Detail
0.011 Carcinoma of lung High-level HGF expression was detected more frequently than EGFR T790M secondary... BeFree 22052230 Detail
0.385 Non-small cell lung carcinoma Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer... BeFree 20421816 Detail
0.385 Non-small cell lung carcinoma Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI ... BeFree 25384171 Detail
<0.001 Carcinoma, Small Cell At present, secondary resistance mechanisms associated with progression are bett... BeFree 23911281 Detail
0.011 Carcinoma of lung Reciprocal and complementary role of MET amplification and EGFR T790M mutation i... BeFree 21062933 Detail
0.385 Non-small cell lung carcinoma The application of real-time PCR technique to detect rare cell clones with prima... BeFree 24789720 Detail
<0.001 Non-small cell lung carcinoma Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversi... BeFree 22891040 Detail
0.385 Non-small cell lung carcinoma Afatinib is a novel TKI that is efficacious and well tolerated in patients with ... BeFree 25349236 Detail
<0.001 Carcinoma of lung Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein o... BeFree 23045273 Detail
<0.001 Carcinoma of lung HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibi... BeFree 17671147 Detail
0.385 Non-small cell lung carcinoma Highly sensitive and noninvasive detection of epidermal growth factor receptor T... BeFree 23886554 Detail
0.080 Carcinoma of lung EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase acti... BeFree 17510392 Detail
0.009 Carcinoma of lung Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lun... BeFree 19351834 Detail
0.200 Adenocarcinoma of lung (disorder) Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR... BeFree 24842519 Detail
<0.001 Small cell carcinoma of lung These efforts have revealed several acquired resistance mechanisms and candidate... BeFree 22736441 Detail
0.001 Lung Neoplasms MET amplification occurs with or without T790M mutations in EGFR mutant lung tum... BeFree 18093943 Detail
0.015 Carcinoma of lung Although the EGF receptor tyrosine kinase inhibitors (EGFR-TKI) erlotinib and ge... BeFree 22844075 Detail
<0.001 Carcinoma, Small Cell At present, secondary resistance mechanisms associated with progression are bett... BeFree 23911281 Detail
0.160 Malignant neoplasm of lung Detection of low-level EGFR T790M mutation in lung cancer tissues. BeFree 21635547 Detail
0.385 Non-small cell lung carcinoma Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)... BeFree 25117641 Detail
0.160 Malignant neoplasm of lung Biochemical analyses of transfected cells and growth inhibition studies with lun... BeFree 15737014 Detail
<0.001 Non-small cell lung carcinoma Interestingly, the NSCLC patients with antigen-specific T cell responses to thes... BeFree 24223798 Detail
0.080 Carcinoma of lung Quantification of epidermal growth factor receptor T790M mutant transcripts in l... BeFree 19961825 Detail
0.385 Non-small cell lung carcinoma This study provides a basis for developing an applicable protocol for detecting ... BeFree 21635547 Detail
0.011 Carcinoma of lung It will be clinically valuable to investigate the involvement of HGF-MET-mediate... BeFree 20008840 Detail
0.002 thymoma The PC-9-derived NSCLC cell lines PC-9ER and PC-9ZD, resistant to EGFR-TKI due t... BeFree 24698130 Detail
0.385 Non-small cell lung carcinoma Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor cod... BeFree 25682017 Detail
0.006 thymoma The PC-9-derived NSCLC cell lines PC-9ER and PC-9ZD, resistant to EGFR-TKI due t... BeFree 24698130 Detail
0.001 Small cell carcinoma of lung EGFR T790M secondary mutation, MET gene amplification, and transformation to sma... BeFree 24939008 Detail
<0.001 Non-small cell lung carcinoma Ibrutinib, which irreversibly inhibits Bruton tyrosine kinase, was evaluated for... BeFree 25214559 Detail
0.009 Carcinoma of lung High-level HGF expression was detected more frequently than EGFR T790M secondary... BeFree 22052230 Detail
0.005 Adenocarcinoma of lung, stage IV Genetic testing revealed two additional EGFR T790M germline carriers, one of whi... BeFree 24736080 Detail
0.160 Malignant neoplasm of lung EGFR T790M mutation: a double role in lung cancer cell survival? BeFree 19096299 Detail
0.080 Carcinoma of lung HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibi... BeFree 17671147 Detail
0.012 Carcinoma of lung Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein o... BeFree 23045273 Detail
0.385 Non-small cell lung carcinoma Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lu... BeFree 25939061 Detail
0.160 Malignant neoplasm of lung The epidermal growth factor receptor (EGFR) mutation T790M is reported in approx... BeFree 21248300 Detail
<0.001 breast carcinoma We examined the mRNA expression of C terminus-binding protein-interacting protei... BeFree 23407556 Detail
0.001 Lung Neoplasms MET amplification occurs with or without T790M mutations in EGFR mutant lung tum... BeFree 18093943 Detail
0.298 Lung Neoplasms Nevertheless, several lines of evidence indicate that the T790M mutation confers... BeFree 19096299 Detail
0.008 Xenograft Model Gö6976 was also shown to significantly reduce tumor growth in an in vivo xenogra... BeFree 21953013 Detail
0.229 Neoplasm Metastasis : Our results imply that blockade of the TGF-β signaling pathway combined with c... BeFree 23334091 Detail
<0.001 Carcinoma, Small Cell At present, secondary resistance mechanisms associated with progression are bett... BeFree 23911281 Detail
0.138 Lung Neoplasms MET amplification occurs with or without T790M mutations in EGFR mutant lung tum... BeFree 18093943 Detail
0.009 Carcinoma of lung Reciprocal and complementary role of MET amplification and EGFR T790M mutation i... BeFree 21062933 Detail
0.009 Carcinoma of lung Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lun... BeFree 19351834 Detail
0.160 Malignant neoplasm of lung HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibi... BeFree 17671147 Detail
0.229 Neoplasm Metastasis The application of real-time PCR technique to detect rare cell clones with prima... BeFree 24789720 Detail
0.009 Carcinoma of lung Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyr... BeFree 23592446 Detail
0.385 Non-small cell lung carcinoma Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversi... BeFree 22891040 Detail
0.011 Malignant neoplasm of lung Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyr... BeFree 23592446 Detail
0.298 Lung Neoplasms Here we used relevant transgenic mouse lung tumor models to evaluate strategies ... BeFree 19759520 Detail
0.011 Malignant neoplasm of lung High-level HGF expression was detected more frequently than EGFR T790M secondary... BeFree 22052230 Detail
0.080 Carcinoma of lung Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T7... BeFree 24736066 Detail
0.008 Xenograft Model We show that resistance to PF00299804 arises, at least in part, through selectio... BeFree 20118985 Detail
0.001 Small cell carcinoma of lung EGFR T790M secondary mutation, MET gene amplification, and transformation to sma... BeFree 24939008 Detail
0.080 Carcinoma of lung Reciprocal and complementary role of MET amplification and EGFR T790M mutation i... BeFree 21062933 Detail
0.160 Malignant neoplasm of lung Lung cancer cell lines made resistant to EGFR-TKIs by the gatekeeper EGFR-T790M ... BeFree 24386407 Detail
0.385 Non-small cell lung carcinoma A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung ... BeFree 25532027 Detail
<0.001 Refractory cancer Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lun... BeFree 19351834 Detail
0.008 Carcinoma of lung Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein o... BeFree 23045273 Detail
0.080 Carcinoma of lung The T790M mutation in EGFR accounts for approximately half of all lung cancer ca... BeFree 26058074 Detail
0.160 Malignant neoplasm of lung Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibi... BeFree 23588221 Detail
<0.001 Small cell carcinoma of lung These efforts have revealed several acquired resistance mechanisms and candidate... BeFree 22736441 Detail
0.018 Non-small cell lung carcinoma Most non-small cell lung cancer (NSCLC) tumors with activating mutations of the ... BeFree 20530710 Detail
0.385 Non-small cell lung carcinoma Ongoing preclinical efforts for treating resistance have started to translate in... BeFree 25296354 Detail
0.160 Malignant neoplasm of lung Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T7... BeFree 24736066 Detail
0.160 Malignant neoplasm of lung Reciprocal and complementary role of MET amplification and EGFR T790M mutation i... BeFree 21062933 Detail
0.005 Adenocarcinoma of lung, stage IV In this article we present a case of a patient suffering from a metastatic lung ... BeFree 20678850 Detail
0.006 Malignant neoplasm of lung Hepatocyte growth factor reduces susceptibility to an irreversible epidermal gro... BeFree 20008840 Detail
0.011 Carcinoma of lung Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lun... BeFree 19351834 Detail
0.009 Carcinoma of lung It will be clinically valuable to investigate the involvement of HGF-MET-mediate... BeFree 20008840 Detail
<0.001 thymoma The PC-9-derived NSCLC cell lines PC-9ER and PC-9ZD, resistant to EGFR-TKI due t... BeFree 24698130 Detail
0.200 Adenocarcinoma of lung (disorder) We also found that an existing EGFR mutant lung adenocarcinoma cell line, NCI-H8... BeFree 18093943 Detail
0.360 adenocarcinoma We analyzed 147 NSCLC tissues [70 adenocarcinomas (AD), 62 squamous cell carcino... BeFree 21635547 Detail
0.011 Malignant neoplasm of lung Reciprocal and complementary role of MET amplification and EGFR T790M mutation i... BeFree 21062933 Detail
0.004 breast carcinoma We examined the mRNA expression of C terminus-binding protein-interacting protei... BeFree 23407556 Detail
0.013 Non-small cell lung carcinoma Enhanced anticancer effect of the combination of BIBW2992 and thymidylate syntha... BeFree 20530710 Detail
0.011 Malignant neoplasm of lung Reciprocal and complementary role of MET amplification and EGFR T790M mutation i... BeFree 21062933 Detail
0.006 Malignant neoplasm of breast We examined the mRNA expression of C terminus-binding protein-interacting protei... BeFree 23407556 Detail
0.009 Carcinoma of lung High-level HGF expression was detected more frequently than EGFR T790M secondary... BeFree 22052230 Detail
0.385 Non-small cell lung carcinoma Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a ... BeFree 24631288 Detail
0.013 Metastatic malignant neoplasm to brain The clinical features of EGFR T790M-mutant lung cancer were similar to those of ... BeFree 25450875 Detail
0.385 Non-small cell lung carcinoma Presence of epidermal growth factor receptor gene T790M mutation as a minor clon... BeFree 16912157 Detail
0.160 Malignant neoplasm of lung Lower gefitinib dose led to earlier resistance acquisition before emergence of T... BeFree 24033722 Detail
0.023 Malignant neoplasm of lung Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lun... BeFree 19351834 Detail
0.160 Malignant neoplasm of lung Clinical outcome according to the level of preexisting epidermal growth factor r... BeFree 24737599 Detail
<0.001 Small cell carcinoma of lung These efforts have revealed several acquired resistance mechanisms and candidate... BeFree 22736441 Detail
0.385 Non-small cell lung carcinoma EGFR gene mutations in the tyrosine kinase(TK) binding domain are predictive of ... BeFree 20718710 Detail
Annotation

Annotations

DescrptionSourceLinks
155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, K... CIViC Evidence Detail
Case report of a patient with stage IV lung adenocarcinoma and a 15–base pair deletion in EGFR exon ... CIViC Evidence Detail
Osimertinib has been approved for the treatment of EGFR T790M mutant NSCLC. CIViC Evidence Detail
48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosi... CIViC Evidence Detail
Patients with advanced NSCLC and acquired resistance to EGFR TKI (gefitinib or erlotinib) were analy... CIViC Evidence Detail
Randomized, international, open-label, phase 3 trial (NCT02151981) in 419 patients with T790M-positi... CIViC Evidence Detail
In a lung adenocarcinoma patient harboring an EGFR E746_A750 mutation and an acquired EGFR T790M co-... CIViC Evidence Detail
In a study of 6 patients with progressive non-small cell lung cancer during gefitinib or erlotinib t... CIViC Evidence Detail
In a study of 14 patients with progressive non-small cell lung cancer during gefitinib, comparison ... CIViC Evidence Detail
In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), i... CIViC Evidence Detail
In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), in... CIViC Evidence Detail
The NSCLC cell line NCI-H1975 carrying the EGFR T790M mutation was resistant to erlotinib but showed... CIViC Evidence Detail
In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), i... CIViC Evidence Detail
In an in vitro study using purified EGFR protein, kinase activity was assayed and compared for wildt... CIViC Evidence Detail
In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), i... CIViC Evidence Detail
The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlo... CIViC Evidence Detail
In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib. CIViC Evidence Detail
In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and ... CIViC Evidence Detail
In an NSCLC patient initially with L858R mutation, pemetrexed and cisplatin combination treatment wa... CIViC Evidence Detail
In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L8... CIViC Evidence Detail
In NSCLC patients with T790M and another activating mutations, their progression free survival is sh... CIViC Evidence Detail
Patients with NSCLC harboring EGFR T790M mutation have statistically worse overall survival compared... CIViC Evidence Detail
Experimental - EGFR T790M mutation has been associated with resistance to first generation EGFR tyro... CIViC Evidence Detail
Lung cancers can accumulate activating mutations in oncogenes such as EGFR. The common L858R EGFR mu... CIViC Evidence Detail
In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparis... CIViC Evidence Detail
CO-1686 (Rociletinib) more effectively induced apoptosis in EGFR mutated (T790M and others) NSCLC ce... CIViC Evidence Detail
Cell line, xenograft, and transgenic models were used to establish Osimertinib as an inhibitor of bo... CIViC Evidence Detail
This phase I/II trial (NCT01802632) involved 253 non-small cell lung cancer patients with activating... CIViC Evidence Detail
This study summarized 9 EGFR-mutant patients from two clinical trials involving rociletinib (NCT0152... CIViC Evidence Detail
For cell harboring EGFR T790M mutation, osimertinib and rociletinib showed potent inhibition compare... CIViC Evidence Detail
NM_005228.5(EGFR):c.2369C>T (p.Thr790Met) AND Nonsmall cell lung cancer, resistance to tyrosine kina... ClinVar Detail
NM_005228.5(EGFR):c.2369C>T (p.Thr790Met) AND Tyrosine kinase inhibitor response ClinVar Detail
NM_005228.5(EGFR):c.2369C>T (p.Thr790Met) AND Non-small cell lung carcinoma ClinVar Detail
NM_005228.5(EGFR):c.2369C>T (p.Thr790Met) AND erlotinib response - Efficacy ClinVar Detail
NM_005228.5(EGFR):c.2369C>T (p.Thr790Met) AND Lung carcinoma ClinVar Detail
NM_005228.5(EGFR):c.2369C>T (p.Thr790Met) AND EGFR-related lung cancer ClinVar Detail
NM_005228.5(EGFR):c.2369C>T (p.Thr790Met) AND Hereditary cancer-predisposing syndrome ClinVar Detail
NM_005228.5(EGFR):c.2369C>T (p.Thr790Met) AND not provided ClinVar Detail
NM_005228.5(EGFR):c.2369C>T (p.Thr790Met) AND gefitinib response - Efficacy ClinVar Detail
NM_005228.5(EGFR):c.2369C>T (p.Thr790Met) AND Lung cancer ClinVar Detail
NM_005228.5(EGFR):c.2369C>T (p.Thr790Met) AND Inflammatory skin and bowel disease, neonatal, 2 ClinVar Detail
NM_005228.5(EGFR):c.2369C>T (p.Thr790Met) AND Lung adenocarcinoma ClinVar Detail
Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors effectively shrunk tum... DisGeNET Detail
Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors effectively shrunk tum... DisGeNET Detail
Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors effectively shrunk tum... DisGeNET Detail
Gefitinib greatly enhanced NK cell cytotoxicity to lung cancer cells with EGFR L858R + T790M resista... DisGeNET Detail
Pharmacologic inhibition of β-catenin suppressed EGFR-L858R-T790M mutated lung tumor growth, and gen... DisGeNET Detail
Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors effectively shrunk tum... DisGeNET Detail
Some of these EGFR-mutated PDXs do not respond to erlotinib: LU1868 containing L858R/T790M mutations... DisGeNET Detail
The in vivo antitumor efficacy study demonstrated that compound 3x significantly inhibited tumor gro... DisGeNET Detail
We used four NSCLC cell lines-A549 (wild-type EGFR), H1650 (mutant EGFR; del E746_A750), H1975 (muta... DisGeNET Detail
Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors effectively shrunk tum... DisGeNET Detail
Some of these EGFR-mutated PDXs do not respond to erlotinib: LU1868 containing L858R/T790M mutations... DisGeNET Detail
Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors effectively shrunk tum... DisGeNET Detail
Gefitinib greatly enhanced NK cell cytotoxicity to lung cancer cells with EGFR L858R + T790M resista... DisGeNET Detail
We used four NSCLC cell lines-A549 (wild-type EGFR), H1650 (mutant EGFR; del E746_A750), H1975 (muta... DisGeNET Detail
Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epi... DisGeNET Detail
Eligible patients included those with relapsed or recurrent advanced NSCLC who progressed after ≥12 ... DisGeNET Detail
We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, ... DisGeNET Detail
Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prog... DisGeNET Detail
Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor ... DisGeNET Detail
We investigated the effect of CK2 inhibition in lung cancer cells with T790M-mediated resistance to ... DisGeNET Detail
Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR... DisGeNET Detail
EGFR T790M secondary mutation, MET gene amplification, and transformation to small cell lung cancer ... DisGeNET Detail
Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for progn... DisGeNET Detail
Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EG... DisGeNET Detail
EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation i... DisGeNET Detail
These inhibitors also show effective inhibition of signaling by T790M-mutant EGFR and killing of NSC... DisGeNET Detail
We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, ... DisGeNET Detail
Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report. DisGeNET Detail
Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibit... DisGeNET Detail
In conclusion, the minor EGFR T790M mutations were present in 13% of EGFR-TKI-naive surgically resec... DisGeNET Detail
We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, ... DisGeNET Detail
Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibit... DisGeNET Detail
We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, ... DisGeNET Detail
Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutati... DisGeNET Detail
The molecular beacon-based approach enabled rapid and sensitive detection of the EGFR mutation (T790... DisGeNET Detail
We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, ... DisGeNET Detail
Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor ... DisGeNET Detail
EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. DisGeNET Detail
Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer. DisGeNET Detail
It will be clinically valuable to investigate the involvement of HGF-MET-mediated signaling in de no... DisGeNET Detail
The PC-9-derived NSCLC cell lines PC-9ER and PC-9ZD, resistant to EGFR-TKI due to v-crk avian sarcom... DisGeNET Detail
Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been li... DisGeNET Detail
EGFR T790M was identified from plasma DNA in 54% (15 of 28) of patients with prior clinical response... DisGeNET Detail
Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibit... DisGeNET Detail
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung ade... DisGeNET Detail
These results suggest that EGFR T790M mutation and c-MET amplification can occur in TKI-resistant NS... DisGeNET Detail
Most non-small cell lung cancer (NSCLC) tumors with activating mutations of the epidermal growth fac... DisGeNET Detail
Together, our results suggest that the identified T cell epitopes might provide a novel immunotherap... DisGeNET Detail
Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinosi... DisGeNET Detail
Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been li... DisGeNET Detail
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in... DisGeNET Detail
It shows preclinical efficacy in NSCLC with common EGFR-activating mutations and the T790M mutation ... DisGeNET Detail
In clinical practice, most patients with non small cell lung cancer (NSCLC) who respond to tyrosine ... DisGeNET Detail
Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells... DisGeNET Detail
Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibit... DisGeNET Detail
At present, secondary resistance mechanisms associated with progression are better known: clonal sel... DisGeNET Detail
Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinosi... DisGeNET Detail
In human lung adenocarcinomas harboring EGFR mutations, a second-site point mutation that substitute... DisGeNET Detail
It will be clinically valuable to investigate the involvement of HGF-MET-mediated signaling in de no... DisGeNET Detail
Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer. DisGeNET Detail
At present, secondary resistance mechanisms associated with progression are better known: clonal sel... DisGeNET Detail
Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinosi... DisGeNET Detail
Post-progression tumor specimens were prospectively collected for T790M mutation analysis in NSCLC p... DisGeNET Detail
We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, ... DisGeNET Detail
To define the incidence of EGFR T790M, we reviewed 2774 sequentially tested patients with lung cance... DisGeNET Detail
We analyzed 147 NSCLC tissues [70 adenocarcinomas (AD), 62 squamous cell carcinomas (SQ), 12 large c... DisGeNET Detail
Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinosi... DisGeNET Detail
Most non-small cell lung cancer (NSCLC) tumors with activating mutations of the epidermal growth fac... DisGeNET Detail
Lung cancer cell lines made resistant to EGFR-TKIs by the gatekeeper EGFR-T790M mutation, Met amplif... DisGeNET Detail
Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinosi... DisGeNET Detail
Cell line-based assays showed that Aki1 constitutively associates with mutant EGFR in lung cancer ce... DisGeNET Detail
High-level HGF expression was detected more frequently than EGFR T790M secondary mutation or MET amp... DisGeNET Detail
Usefulness of nanofluidic digital PCR arrays to quantify T790M mutation in EGFR-mutant lung adenocar... DisGeNET Detail
AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had dise... DisGeNET Detail
Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been li... DisGeNET Detail
These efforts have revealed several acquired resistance mechanisms and candidates, including EGFR se... DisGeNET Detail
Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinosi... DisGeNET Detail
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistanc... DisGeNET Detail
EGFR T790M was identified from plasma DNA in 54% (15 of 28) of patients with prior clinical response... DisGeNET Detail
Furthermore, both agents and their combination almost completely prevented TKI-resistant tumor forma... DisGeNET Detail
At present, secondary resistance mechanisms associated with progression are better known: clonal sel... DisGeNET Detail
Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been li... DisGeNET Detail
Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibit... DisGeNET Detail
We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, ... DisGeNET Detail
EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation i... DisGeNET Detail
Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prog... DisGeNET Detail
The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell dea... DisGeNET Detail
Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. DisGeNET Detail
Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells... DisGeNET Detail
Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor ... DisGeNET Detail
We analyzed 147 NSCLC tissues [70 adenocarcinomas (AD), 62 squamous cell carcinomas (SQ), 12 large c... DisGeNET Detail
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents i... DisGeNET Detail
: Our results imply that blockade of the TGF-β signaling pathway combined with continuous EGFR TKI t... DisGeNET Detail
The three major clinically relevant mechanisms of acquired resistance to epidermal growth factor rec... DisGeNET Detail
Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have been introduce... DisGeNET Detail
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired re... DisGeNET Detail
HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibit the growth of T790... DisGeNET Detail
High-level HGF expression was detected more frequently than EGFR T790M secondary mutation or MET amp... DisGeNET Detail
Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinosi... DisGeNET Detail
The PC-9-derived NSCLC cell lines PC-9ER and PC-9ZD, resistant to EGFR-TKI due to v-crk avian sarcom... DisGeNET Detail
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EG... DisGeNET Detail
Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine k... DisGeNET Detail
Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines ... DisGeNET Detail
DNA from 124 pretreatment tissue samples from patients with advanced non-small-cell lung cancer carr... DisGeNET Detail
It will be clinically valuable to investigate the involvement of HGF-MET-mediated signaling in de no... DisGeNET Detail
At present, secondary resistance mechanisms associated with progression are better known: clonal sel... DisGeNET Detail
We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, ... DisGeNET Detail
Cell line-based assays showed that Aki1 constitutively associates with mutant EGFR in lung cancer ce... DisGeNET Detail
We analyzed 147 NSCLC tissues [70 adenocarcinomas (AD), 62 squamous cell carcinomas (SQ), 12 large c... DisGeNET Detail
There is limited information available concerning the prevalence of primary T790M mutations in patie... DisGeNET Detail
EGFR T790M mutation: a double role in lung cancer cell survival? DisGeNET Detail
The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell dea... DisGeNET Detail
We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, ... DisGeNET Detail
Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinosi... DisGeNET Detail
Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by ... DisGeNET Detail
Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resista... DisGeNET Detail
There is a possibility to detect the primary T790M mutation in brain metastases of NSCLC in EGFR-TKI... DisGeNET Detail
Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinosi... DisGeNET Detail
We investigated the effect of CK2 inhibition in lung cancer cells with T790M-mediated resistance to ... DisGeNET Detail
Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been li... DisGeNET Detail
Although the EGF receptor tyrosine kinase inhibitors (EGFR-TKI) erlotinib and gefitinib have shown d... DisGeNET Detail
A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance. DisGeNET Detail
These efforts have revealed several acquired resistance mechanisms and candidates, including EGFR se... DisGeNET Detail
Detection of low-level EGFR T790M mutation in lung cancer tissues. DisGeNET Detail
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistanc... DisGeNET Detail
The PC-9-derived NSCLC cell lines PC-9ER and PC-9ZD, resistant to EGFR-TKI due to v-crk avian sarcom... DisGeNET Detail
Although epidermal growth factor receptor (EGFR) kinase inhibitors are effective for the treatment o... DisGeNET Detail
EGFR T790M secondary mutation, MET gene amplification, and transformation to small cell lung cancer ... DisGeNET Detail
The T790M mutation in EGFR accounts for approximately half of all lung cancer cases with acquired re... DisGeNET Detail
AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had dise... DisGeNET Detail
To define the incidence of EGFR T790M, we reviewed 2774 sequentially tested patients with lung cance... DisGeNET Detail
It will be clinically valuable to investigate the involvement of HGF-MET-mediated signaling in de no... DisGeNET Detail
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in... DisGeNET Detail
Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lu... DisGeNET Detail
Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. DisGeNET Detail
These efforts have revealed several acquired resistance mechanisms and candidates, including EGFR se... DisGeNET Detail
Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibit... DisGeNET Detail
At present, secondary resistance mechanisms associated with progression are better known: clonal sel... DisGeNET Detail
These efforts have revealed several acquired resistance mechanisms and candidates, including EGFR se... DisGeNET Detail
Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung t... DisGeNET Detail
A lung biopsy from the left lower lobe disclosed an adenocarcinoma which harbored an in-frame deleti... DisGeNET Detail
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in... DisGeNET Detail
These results suggest that EGFR T790M mutation and c-MET amplification can occur in TKI-resistant NS... DisGeNET Detail
High-level HGF expression was detected more frequently than EGFR T790M secondary mutation or MET amp... DisGeNET Detail
Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modu... DisGeNET Detail
Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-... DisGeNET Detail
At present, secondary resistance mechanisms associated with progression are better known: clonal sel... DisGeNET Detail
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistanc... DisGeNET Detail
The application of real-time PCR technique to detect rare cell clones with primary T790M Substitutio... DisGeNET Detail
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors ... DisGeNET Detail
Afatinib is a novel TKI that is efficacious and well tolerated in patients with NSCLC associated wit... DisGeNET Detail
Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinosi... DisGeNET Detail
HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibit the growth of T790... DisGeNET Detail
Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non... DisGeNET Detail
EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. DisGeNET Detail
Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been li... DisGeNET Detail
Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung a... DisGeNET Detail
These efforts have revealed several acquired resistance mechanisms and candidates, including EGFR se... DisGeNET Detail
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired re... DisGeNET Detail
Although the EGF receptor tyrosine kinase inhibitors (EGFR-TKI) erlotinib and gefitinib have shown d... DisGeNET Detail
At present, secondary resistance mechanisms associated with progression are better known: clonal sel... DisGeNET Detail
Detection of low-level EGFR T790M mutation in lung cancer tissues. DisGeNET Detail
Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have been introduce... DisGeNET Detail
Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines ... DisGeNET Detail
Interestingly, the NSCLC patients with antigen-specific T cell responses to these epitopes showed a ... DisGeNET Detail
Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by ... DisGeNET Detail
This study provides a basis for developing an applicable protocol for detecting low-level EGFR T790M... DisGeNET Detail
It will be clinically valuable to investigate the involvement of HGF-MET-mediated signaling in de no... DisGeNET Detail
The PC-9-derived NSCLC cell lines PC-9ER and PC-9ZD, resistant to EGFR-TKI due to v-crk avian sarcom... DisGeNET Detail
Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications... DisGeNET Detail
The PC-9-derived NSCLC cell lines PC-9ER and PC-9ZD, resistant to EGFR-TKI due to v-crk avian sarcom... DisGeNET Detail
EGFR T790M secondary mutation, MET gene amplification, and transformation to small cell lung cancer ... DisGeNET Detail
Ibrutinib, which irreversibly inhibits Bruton tyrosine kinase, was evaluated for antitumor activity ... DisGeNET Detail
High-level HGF expression was detected more frequently than EGFR T790M secondary mutation or MET amp... DisGeNET Detail
Genetic testing revealed two additional EGFR T790M germline carriers, one of which was subsequently ... DisGeNET Detail
EGFR T790M mutation: a double role in lung cancer cell survival? DisGeNET Detail
HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibit the growth of T790... DisGeNET Detail
Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinosi... DisGeNET Detail
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring ... DisGeNET Detail
The epidermal growth factor receptor (EGFR) mutation T790M is reported in approximately 50% of lung ... DisGeNET Detail
We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, ... DisGeNET Detail
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired re... DisGeNET Detail
Nevertheless, several lines of evidence indicate that the T790M mutation confers growth advantage to... DisGeNET Detail
Gö6976 was also shown to significantly reduce tumor growth in an in vivo xenograft model with a EGFR... DisGeNET Detail
: Our results imply that blockade of the TGF-β signaling pathway combined with continuous EGFR TKI t... DisGeNET Detail
At present, secondary resistance mechanisms associated with progression are better known: clonal sel... DisGeNET Detail
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired re... DisGeNET Detail
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistanc... DisGeNET Detail
Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been li... DisGeNET Detail
HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibit the growth of T790... DisGeNET Detail
The application of real-time PCR technique to detect rare cell clones with primary T790M Substitutio... DisGeNET Detail
Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibit... DisGeNET Detail
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors ... DisGeNET Detail
Clinical resistance to gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibit... DisGeNET Detail
Here we used relevant transgenic mouse lung tumor models to evaluate strategies to overcome the most... DisGeNET Detail
High-level HGF expression was detected more frequently than EGFR T790M secondary mutation or MET amp... DisGeNET Detail
Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. DisGeNET Detail
We show that resistance to PF00299804 arises, at least in part, through selection of a pre-existing ... DisGeNET Detail
EGFR T790M secondary mutation, MET gene amplification, and transformation to small cell lung cancer ... DisGeNET Detail
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistanc... DisGeNET Detail
Lung cancer cell lines made resistant to EGFR-TKIs by the gatekeeper EGFR-T790M mutation, Met amplif... DisGeNET Detail
A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer. DisGeNET Detail
Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been li... DisGeNET Detail
Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinosi... DisGeNET Detail
The T790M mutation in EGFR accounts for approximately half of all lung cancer cases with acquired re... DisGeNET Detail
Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lu... DisGeNET Detail
These efforts have revealed several acquired resistance mechanisms and candidates, including EGFR se... DisGeNET Detail
Most non-small cell lung cancer (NSCLC) tumors with activating mutations of the epidermal growth fac... DisGeNET Detail
Ongoing preclinical efforts for treating resistance have started to translate into patient care (inc... DisGeNET Detail
Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. DisGeNET Detail
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistanc... DisGeNET Detail
In this article we present a case of a patient suffering from a metastatic lung adenocarcinoma with ... DisGeNET Detail
Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor ... DisGeNET Detail
Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been li... DisGeNET Detail
It will be clinically valuable to investigate the involvement of HGF-MET-mediated signaling in de no... DisGeNET Detail
The PC-9-derived NSCLC cell lines PC-9ER and PC-9ZD, resistant to EGFR-TKI due to v-crk avian sarcom... DisGeNET Detail
We also found that an existing EGFR mutant lung adenocarcinoma cell line, NCI-H820, harbors MET ampl... DisGeNET Detail
We analyzed 147 NSCLC tissues [70 adenocarcinomas (AD), 62 squamous cell carcinomas (SQ), 12 large c... DisGeNET Detail
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistanc... DisGeNET Detail
We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, ... DisGeNET Detail
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents i... DisGeNET Detail
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistanc... DisGeNET Detail
We examined the mRNA expression of C terminus-binding protein-interacting protein and Lin11, Isl-1, ... DisGeNET Detail
High-level HGF expression was detected more frequently than EGFR T790M secondary mutation or MET amp... DisGeNET Detail
Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung ... DisGeNET Detail
The clinical features of EGFR T790M-mutant lung cancer were similar to those of sensitive EGFR-mutan... DisGeNET Detail
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell ... DisGeNET Detail
Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epi... DisGeNET Detail
Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been li... DisGeNET Detail
Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutati... DisGeNET Detail
These efforts have revealed several acquired resistance mechanisms and candidates, including EGFR se... DisGeNET Detail
EGFR gene mutations in the tyrosine kinase(TK) binding domain are predictive of response to EGFR tyr... DisGeNET Detail

Overlapped Transcript Coordinates

Gene Transcript ID Exon Number Chromosome Start Stop Type Amino Mutation Transcript Position Links

Overlapped Transcript

Gene Transcript ID Chromosome Start Stop Links
Gene
-
dbSNP
rs121434569 dbSNP
Genome
hg38
Position
chr7:55,181,378-55,181,378
Variant Type
snv
Reference Allele
C
Alternative Allele
T
East Asian Chromosome Counts (ExAC)
8640
East Asian Allele Counts (ExAC)
0
East Asian Heterozygous Counts (ExAC)
0
East Asian Homozygous Counts (ExAC)
0
East Asian Allele Frequency (ExAC)
0.0
Chromosome Counts in All Race (ExAC)
121292
Allele Counts in All Race (ExAC)
5
Heterozygous Counts in All Race (ExAC)
5
Homozygous Counts in All Race (ExAC)
0
Allele Frequency in All Race (ExAC)
4.122283415229364E-5
Variant (CIViC) (CIViC Variant)
T790M
Transcript 1 (CIViC Variant)
ENST00000275493.2
Variant URL (CIViC Variant)
https://civic.genome.wustl.edu/links/variants/34
Summary (CIViC Variant)
EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.
Genome browser